Form 4: Corcept Therapeutics CFO Atabak Mokari Reports Stock Transactions

Atabak Mokari, CFO of Corcept Therapeutics, reports acquisition and disposal of company stock, including shares withheld for tax obligations and shares acquired through a purchase plan.

Summary

• Atabak Mokari, the Chief Financial Officer of Corcept Therapeutics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 3, 2025, shares were withheld by the issuer to cover tax obligations related to the vesting of restricted stock units; 228 shares were disposed of at a price of $60.58.
• Also on March 3, 2025, Mokari acquired 232 shares through a purchase plan at $59.07 per share and another 232 shares under unvested restricted stock awards at $0.
• Following these transactions, Mokari directly owns 13,034 shares of Corcept Therapeutics common stock.
• Mokari was also granted stock options to purchase 140,000 shares at an exercise price of $60.58, which vest monthly over four years starting February 28, 2025, expiring on February 28, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing detailing stock transactions. The CFO's participation in the stock purchase plan could be seen as a slightly positive signal.

Positives

• The acquisition of shares through the purchase plan demonstrates the CFO's investment in the company's stock.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options and restricted stock awards.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and employee stock purchase plans are common compensation tools used by companies like Corcept Therapeutics to align management's interests with those of shareholders.
• The vesting schedule of the stock options (monthly over four years) is a typical arrangement to incentivize long-term commitment.
• The size of the stock option grant (140,000 shares) is within the range of what is seen at comparable companies, but the specific amount would depend on the CFO's overall compensation package and the company's equity grant policies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock.

Key Dates